Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > 3 shares traded? Am I reading that right?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(559)
•••
Comment by chrispion Mar 21, 2021 9:52pm
175 Views
Post# 32848224

RE:RE:RE:RE:RE:RE:RE:RE:3 shares traded? Am I reading that right?

RE:RE:RE:RE:RE:RE:RE:RE:3 shares traded? Am I reading that right?
Wether discussed here or a civilized forum like you just said makes no difference how this trades....
it trades like a hot sht after a night of eating wings amd beers ...
no interest... no volume ... no deals and no action

suck it! 

We'll in a civilized forum we'd do a spell check before posting but I digress ...

Recall from some of my past posts, which I'm sure you have seen since you berate me for them ;), company defining news can happen at any time, and when the market least expects it. That's how you get a forgotten biotech stock suddenly going up 400% on some trial results or partnership news. That's how you get a biotech buyout for a 125% premium when it looked like the stock chart of that company had flatlined for the longest time. Sometimes you find out the real value of a company is not necessarily what the stock market awards it each day when it is traded Monday thru Friday on the exhange but rather when another company realizes how valuable it is for their needs and to meet their future goals AND how valuable it is to keep it out of competitors' hands.

Cogitate that.
Ooops, let me use easier to understand words ... think about that.
Then reply back over here please

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities